APAC Alopecia Market

APAC Alopecia Market Size (2023 to 2028)

The Asia pacific alopecia Market was worth USD 2.21 billion in 2023 and is estimated to grow at a CAGR of 10.77% to reach USD 3.69 billion by 2028.

Alopecia is a medical condition that refers to sudden, excessive hair loss on the head area, mostly in circular patches. One such type of alopecia - Alopecia areata is a common autoimmune disease that causes baldness that results in partial or complete hair loss.

The primary driver of the APAC alopecia market is the rising demand for effective hair loss treatment pharmaceuticals, particularly oral treatments. Oral hair loss treatment medicines are becoming more popular since they help to ensure patient safety by reducing the number of prescription dosages while increasing therapeutic efficacy.

Other factors expected to fuel the market growth for alopecia treatment over the forecast period include increased stress levels among working-class populations, cosmeceutical drug manufacturers focusing on expanding their hair treatment and scalp treatment product lines, and cytokine therapy gaining traction for alopecia treatment. Either public or private payers do not reimburse most laser treatment services. Such services have a wide range of prices, and there is no way to standardize them.

Due to the increased penetration of alopecia products, rising disposable income, and expanding consumer spending, the market in the Asia Pacific is expected to grow at the fastest rate throughout the forecast period. Furthermore, as the regulatory environment in emerging nations improves, multinational businesses are expected to invest and take advantage of the available market prospects.

However, The growth of the APAC alopecia treatment market is projected to be hampered by the patent expiration of major pharmaceuticals, resulting in market exclusivity for particular brands and significant adverse effects connected with hair loss treatments. Allergies, melancholy, and the possibility of chronic sexual dysfunction are some of the adverse effects. The limited efficacy of hair loss treatment pharmaceuticals and a lack of reimbursement facilities for hair loss treatment services, such as laser treatments, are further market deterrents. The market's expansion is also being hampered by limited efficacy and a lack of evidence demonstrating the therapeutic usefulness of present hair loss medicines.

This research report on the APAC alopecia market has been segmented and sub-segmented into the following categories:

By Disease Type:

• Alopecia Areata
  • Male
  • Female
• Cicatricial Alopecia
  • Male
  • Female
• Traction Alopecia
  • Male
  • Female
• Alopecia Totalis
  • Male
  • Female
• Alopecia Universalis
  • Male
  • Female
• Androgenetic Alopecia
  • Male
  • Female
• Others
  • Male
  • Female

By Treatment:

• Pharmaceuticals
• Devices

By Gender:

• Male
• Female

By Sales Channel:

• Prescriptions
• OTC

By End Use:

• Homecare Settings
• Dermatology Clinics

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Asia-Pacific is expected to develop at the quickest CAGR because alopecia treatment (hair loss) is rapidly expanding in Asia-Pacific countries due to the rapidly increasing male population and increasing awareness about hair loss treatment. The Asia-Pacific market is projected to be dominated by Japan. However, China is one of the world's leading countries, with fast-changing lifestyles, increased medical device manufacture, and increased use of herbal supplements.

Hair loss treatment in Asia-Pacific is expected to surpass current volume consumption, primarily driven by an aging population, rising stress among the young, and pollution concerns, which are some of the key factors driving the APAC alopecia market. In addition, growing pollution and dietary changes are causing more significant hair loss issues in developing countries such as China and India, which is predicted to affect hair loss treatment product sales in these countries. The iGrow laser system by Apira Science was approved by the China Food and Drug Administration, making it the first laser-based hair growth technology to be certified in China.

KEY MARKET PLAYERS:

Invacare Corporation, Carex Health Brands, Ottobock, Sunrise Medical Limited, Drive Medical Design & Manufacturing, Pride Mobility Products Corp., and GF Health Products, Inc. are a few prominent companies operating in the APAC alopecia market.